Comparative Pharmacology
Head-to-head clinical analysis: LEGUBETI versus SPRX 105.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEGUBETI versus SPRX 105.
LEGUBETI vs SPRX-105
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Legubeti is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin secretion.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
500 mg orally twice daily
SPRX-105 is administered orally at a dose of 50 mg once daily.
None Documented
None Documented
Terminal half-life: 12 hours; steady-state reached after 2-3 days; adjust dose in renal impairment
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Category C
Category C
Unknown
Unknown